Fang Wu (Presenter)
Authorship: Fang Wu(1), Roberta Melis(2), Gwendolyn A. McMillin (2,3)
(1) Department of Laboratory Medicine and Pathology, Saskatoon Health Region, Saskatoon, SK, Canada, S7W 0S1; (2) ARUP Laboratories, Salt Lake City, UT, USA, 84108; (3) Department of Pathology, University of Utah, Salt Lake City, UT,USA, 84132,
After an overview of background information in Segment I, the presenter will discuss the implementation process. Attendees are encouraged to participate in classroom discussions. The challenges of implementing MALDI-TOF/MS PGx tests will be discussed as well with the main focus on cost, personnel, turnaround time and technical difficulties. Several practical considerations for the implementation will also be considered, e.g. space and workflow automation.
Conclusions & Discussion
After this segment, participants should be able to 1)identify the advantages and limitations of MALDI-TOF/MS in PGx testing; 2) create a practical laboratory preparation plan to set up MALDI-TOF/MS PGx testing.
References & Acknowledgements:
IP Royalty: no
|Planning to mention or discuss specific products or technology of the company(ies) listed above:||